Develops monoclonal antibodies for viral infectious diseases, including COVID-19 and measles.
Jun 2026Revenue $58.4M/yrExpenses $171M/yr
No trendCash runway ≈ 1.5 years from Jun 2026
Figures by year
When will Invivyd be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $58.4M and expenses $171M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $53.4M | $109M | −$55.6M |
| Dec 2024 | $25.4M | $202M | −$177M |
| Dec 2023 | $0.00 | $213M | −$213M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.